MCCUNE R M, TOMPSETT R
J Exp Med. 1956 Nov 1;104(5):737-62. doi: 10.1084/jem.104.5.737.
Observations are presented on the behavior of populations of tubercle bacilli in the tissues of mice during the administration of antimicrobial drugs. The behavior of the populations during therapy with any particular drug was different depending upon whether the tubercle bacilli were subsisting in the lung or in the spleen. Moreover, the pattern of microbial behavior was distinctive and predictable for each drug studied. Changes in the size of the populations of tubercle bacilli in the tissues appeared to be a more sensitive reflection of drug influence than microscopic study of the number and character of the tuberculous lesions. Nevertheless, in untreated animals, pulmonary lesions evolved and progressed steadily to a fatal outcome despite the fact that the populations of tubercle bacilli had stabilized at a relatively high census early in the course of therapy. The uniform persistence of tubercle bacilli in the spleen throughout prolonged drug administration was demonstrated with every drug or multiple drug regimens except for pyrazinamide when accompanied by isoniazid. Cultures of the bacilli which survived in the tissues despite antimicrobial therapy were highly susceptible to the drugs employed when tested in vitro. Thus the survival of the tubercle bacilli in the tissues represented microbial persistence rather than drug resistance. When pyrazinamide and isoniazid were administered together, it was not possible to detect the microorganisms in the spleen or lungs of treated animals. A detailed investigation of this apparent abolition of microbial persistence forms the subject of an accompanying report.
本文呈现了在给予抗菌药物期间,结核杆菌群体在小鼠组织中的行为观察结果。在使用任何一种特定药物治疗期间,结核杆菌群体的行为因它们存在于肺部还是脾脏而有所不同。此外,对于所研究的每种药物,微生物行为模式都是独特且可预测的。与对结核病变的数量和特征进行显微镜研究相比,组织中结核杆菌群体大小的变化似乎更能敏感地反映药物的影响。然而,在未经治疗的动物中,尽管在治疗早期结核杆菌群体已稳定在相对较高的数量,但肺部病变仍持续发展并最终导致致命结果。除了吡嗪酰胺与异烟肼联用时外,在长期给予每种药物或多种药物治疗方案的过程中,脾脏中的结核杆菌始终持续存在。尽管接受了抗菌治疗,但在组织中存活下来的杆菌培养物在体外测试时对所用药物高度敏感。因此,组织中结核杆菌的存活代表的是微生物的持续存在而非耐药性。当同时给予吡嗪酰胺和异烟肼时,在接受治疗的动物的脾脏或肺部中无法检测到微生物。对这种明显消除微生物持续存在现象的详细研究构成了一篇配套报告的主题。